Skip to main content
editorial
. 2010 Sep 27;2(9):325–336. doi: 10.4254/wjh.v2.i9.325

Figure 3.

Figure 3

Proportion of solid organ transplant patients with resolution of clinical symptoms (panel A) and viremia eradication (panel B) at day 21 and 49 following the start of valganciclovir or intravenous ganciclovir treatment of CMV disease. Data obtained from the study by Asberg and colleagues[79].